Luspatercept real-world data confirms 46.6% HI-E, 30.9% 16-week TI in MDS.
Background
Patients with lower-risk myelodysplastic neoplasms (MDS) often suffer from chronic anemia, necessitating frequent red blood cell transfusions. This transfusion dependency significantly impacts quality of life and carries risks like iron overload. Current standard-of-care options may fall short for many, highlighting a critical need for therapies that promote endogenous erythropoiesis. Luspatercept, an erythroid maturation agent, addresses this by targeting later-stage erythroid precursors, offering a mechanism to reduce transfusion burden and improve hematologic parameters in this challenging patient population.
Study Design
This systematic review and Bayesian meta-analysis synthesized real-world evidence on luspatercept effectiveness and safety. Following PRISMA guidelines, researchers searched for studies up to June 2025, evaluating luspatercept in adult MDS patients. The analysis included 17 studies: five clinical trials (440 patients) and twelve real-world cohorts (1821 patients). Data extracted included hematologic improvement-erythroid (HI-E), transfusion independence (TI) at 8, 12, and 16 weeks, adverse events, and overall survival (OS). Bayesian random-effects meta-analyses used priors derived from pooled clinical trials.
Results
Real-world evidence for luspatercept demonstrated significant hematologic improvements. The pooled estimate for hematologic improvement-erythroid (HI-E) was 46.6% (95% CrI: 32.5%-63.9%). Transfusion independence (TI) rates showed a gradual decrease over time, with pooled rates of 44.7% (95% CrI: 28.6%-61.5%) at 8 weeks, 38.6% (95% CrI: 21.1%-60.0%) at 12 weeks, and 30.9% (95% CrI: 10.7%-53.9%) at 16 weeks. Subgroup analyses revealed notable differences: patients with positive SF3B1 status achieved the highest TI rate (58.5% at 8 weeks), while Asian patients showed the highest HI-E (54.8%). Male sex was associated with lower HI-E, 8-week, and 12-week TI rates.
Overall survival rates were estimated at 88.9% at 1 year and 74.4% at 2 years following treatment initiation. Adverse events like hypertension and falls were more frequently reported in real-world settings compared to controlled trials, and real-world HI-E was modestly attenuated, likely due to differences in patient selection, adherence, and monitoring.
Key Findings
- Pooled
hematologic improvement-erythroid (HI-E)rate was 46.6% (95% CrI: 32.5%-63.9%). - Pooled
transfusion independence (TI)at 16 weeks was 30.9% (95% CrI: 10.7%-53.9%). SF3B1positive patients showed highest TI (58.5% at 8 weeks).- Asian patients had highest HI-E (54.8%).
- 1-year overall survival was 88.9%, and 2-year OS was 74.4%.
Why It Matters
This meta-analysis provides crucial validation for luspatercept's efficacy in real-world MDS patients, reinforcing its role beyond controlled trial settings. The findings underscore the importance of patient-specific factors like SF3B1 mutation status, ethnicity, and sex in predicting treatment response, suggesting a more personalized approach to therapy. Clinicians should consider these demographic and disease moderators when making treatment decisions and designing future studies. While real-world HI-E was slightly lower, the robust TI and OS rates offer reassurance. This data helps bridge the gap between clinical trial results and practical application, informing patient selection and management strategies for optimizing outcomes in lower-risk MDS.
luspatercept
myelodysplastic-neoplasms
mds
anemia
erythroid-maturation
meta-analysis